A chemist by training, Jeff has more than 22 years experience managing clinical research, education and advocacy programs in HIV and malaria. Prior to joining University of Maryland in 2010, Jeff led the research and educational efforts of The Foundation for AIDS Research's (amfAR) TREAT Asia program. The focus of Jeff's work in the past decade has been building capacity for sustainable HIV and malaria drug resistance surveillance systems in Asia-Pacific region. Jeff cultivates a holistic approach to combating disease by integrating research, education and advocacy components into treatment and care programs.
Jeff is Coordinator for the Mekong Molecular Surveillance Network, a collaborative group of scientists and laboratories in Cambodia, China, Lao PDR, Myanmar, Thailand and Vietnam aiming to improve surveillance of antimalarial drug resistance by employing high quality and innovative molecular tools. Jeff also serves as Director of Asia for the World-Wide Antimalarial Resistance Network (WWARN), a global organization working to track the emergence and spread of antimalarial drug resistance. His primary interest is in understanding the evolution and spread of drug resistance and developing effective and sustainable approaches to containing and eliminating drug resistance pathogens.
Land S, Cunningham P, Zhou J, Frost K, Katzenstein D, Kantor R, Chen YMA, Oka S, DeLong A, Sayer D, Smith J, Dax EM, and Law M on behalf of the TAQAS Laboratory Network. 2009. The TREAT Asia Quality Assessment Scheme to Standardize the Outcome of HIV Genotypic Resistance Testing in a Group of Asian Laboratories. Journal of Virological Methods 159: 185-193.
Srasuebkul P, Lim PL, Lee MP, Kumarasamy N, Zhou J, Sirisanthana T, Li PC, Kamarulzaman A, Oka S, Phanuphak P, Vonthanak S, Merati TP, Chen YM, Sungkanuparph S, Tau G, Zhang F, Lee CK, Ditangco R, Pujari S, Choi JY, Smith J, Law MG. 2009. Short-Term Clinical Disease Progression in HIV-Infected Patients Receiving Combination Antiretroviral Therapy: Results from the TREAT Asia HIV Observational Database. Clinical Infectious Diseases 48:940-950.
Brau N, Rodriguez-Torres M, Prokupek D, Bonacini M, Giffen CA, Smith JJ, Frost KR, and Kostman JR for the amfAR DCRI 010 Study Group. 2004. Treatment of Chronic Hepatitis C in HIV/HCV-Coinfection with Interferon alfa-2b + Full-Course vs. 16-Week Delayed Ribavirin. Hepatology 39:989-998.
Leoung GS, Stanford JF, Giordano MF, Stein A, Torres RA, Giffen CA, Wesley M, Sarracco T, Cooper EC, Dratter V, Smith JJ, and Frost KR for the amfAR Community-Based Clinical Trials Network. 2001. Trimethoprim/Sulfamethoxazole (TMP/SMZ) Dose Escalation versus Direct Rechallenge for PCP Prophylaxis in HIV-Infected Persons with Previous Adverse Reaction to TMP/SMZ. Journal of Infectious Diseases 184:992-997.
Hellinger JA, Iwane MK, Smith JJ, Fleishman AN, Torres RA, Schrader S, Perez G, Cohen CJ, Skowron G, Giordano MF, Acceta G, Cooper EC, and Frost KR for the American Foundation for AIDS Research Community-Based Clinical Trials Network. 2000. A Randomized Study of the Safety and Antiretroviral Activity of Hydroxyurea Combined with Didanosine in Persons Infected with Human Immunodeficiency Virus Type 1. Journal of Infectious Diseases 181:540-547.
Smith J. 1995. Nutritional Aspects of HIV/AIDS. AIDS/HIV Treatment Directory 7:7-11.
Barkley C, York JP, Badalament RA, Nesbitt JA, Smith JJ, and Drago JR. 1993. Testicular Torsion and its Effect on Contralateral Testicle. Urology 41:192-194.
Drago JR and Smith J. 1991. The Use of the Nb Rat in Combination Chemotherapeutic Experiments for Prostate Cancer. In Vivo 5:41-42.
Badalament RA, Smith JJ, Franklin GL, and Drago JR. 1990. DNA Ploidy Analysis of Invasive Bladder Cancer by Flow Cytometry. In Vivo 4:269-272.
York JP, Klump R, Smith JJ, and Drago JR. 1990. The Role of the Adrenal in the Rat Varicocele Model. In Vivo 4:145-147.
Drago JR, Nesbitt JA, Smith JJ, Geraniotis E, and Cirulli C. 1989. Simple Continence-Maintaining Ileal Valve. Urology 31:429-430.
Drago JR, Nesbitt JA, Smith JJ, Picklow T, Shah BN, Nelson JH, and Wise HA. 1989. ESWL Treatment of Urinary Calculi. Urology 33:400-403.
Drago JR, Badalament RA, Wientjes MG, Smith JJ, Nesbitt JA, York JP, Ashton JJ, and Neff JC. 1989. The Relative Value of Prostatic-Specific Antigen and Prostatic Acid Phosphatase in the Diagnosis and Management of Adenocarcinoma of the Prostate: The Ohio State Experience. Urology 34:187-192.
Wientjes G, Smith J, Miller R, Badalament RA, and Drago JR. 1989. Noble PRST-1 Ca Prostate Adenocarcinoma Study on Noble Rats: Preliminary Study on New Androgen Sensitive Tumor. In Vivo 3:335-337.
Byard MA, Smith JJ, and Drago JR. 1989. Chemotesting of Prostate Cancer Xenografts. Journal of Surgical Oncology 41:198-200.
Klump R, Pieters RC, Smith JJ, Badalament RA, and Drago JR. 1989. Radiotherapy and Concomitant Chemoradiotherapy in the NB Rat Prostate Adenocarcinoma Model. In Vivo 3:109-111.
Drago JR, Nesbitt JA, Smith J, Geraniotis E, and Cirulli C. 1988. Simple Continence-Maintaining Ileal Valve. Urology 31:429-430.
Drago JR, Nesbitt JA, McDowell G, Cirulli C, Geraniotis E, and Smith J. 1988. Experimental Continent Diversion. Journal of Surgical Oncology 37:252-256.
Drago JR, Nesbitt JA, Badalament RA, and Smith JJ. 1988. Chemotherapy and Vitamin E in Treatment of Nb Rat Prostate Tumors. In Vivo 2:399-401.
Nesbitt JA, Smith J, McDowell G, and Drago JR. 1988. Adriamycin-Vitamin E Combination Therapy for Treatment of Prostate Adenocarcinoma in the Nb Rat Model. Journal of Surgical Oncology 38:283-284.
Drago JR and Smith JJ. 1987. First-Generation Human Renal Cell Carcinoma Xenografts in the Nb Rat Subrenal Capsular Assay Model. In Vivo 1:57-59.